Description

Technical Parameters

Upadacitinib is a small molecule drug that is primarily used for the treatment of various autoimmune diseases, particularly rheumatoid arthritis.

Upadacitinib (ABT-494) CAS 1310726-60-3 is a potent and selective Janus kinase (JAK) 1 inhibitor.

Upadacitinib CAS 1310726-60-3

Product: Upadacitinib CAS 1310726-60-3
Another Name: Upadacitinib; ABT-494; ABT-494 (Upadacitinib) free base; ABT-494 (Upadacitinib);
Chemical Name: (3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-1-pyrrolidinecarboxamide
Molecular formula: C₁₇H₁₉F₃N₆O
Molecular mass: 380.37
CAS No.: 1310726-60-3
MDL Number: MFCD30502663
Upadacitinib Intermediates: CAS 1428243-26-8; CAS 1201187-44-1; CAS 1428243-28-0

Upadacitinib is used to treat multiple autoimmune diseases and is primarily indicated for the following conditions:

1. Rheumatoid arthritis: Used to treat moderate to severe refractory rheumatoid arthritis that is unresponsive to first-line therapy.

2. Ankylosing spondylitis: Used to treat moderate to severe ankylosing spondylitis.

3. Juvenile idiopathic arthritis: Used to treat juvenile idiopathic arthritis in patients aged 2 years and older.

4. Psoriatic arthritis: Used to treat moderate to severe psoriatic arthritis.

5. Ulcerative colitis: Used to treat moderate to severe ulcerative colitis.

1. Payment term

TT, LC

2. Delivery date

Negotiable

3. Market

Middle East / Africa / Asia / South America / Europe

4. Sample

Available
5. Executive standards
YBH/JP

6. Qualification certificate

Registration "A" status of raw material packaging, Notification of Approval of marketing

7. Packaging size specification

Inner package: single-layer polyethylene bag and aluminum foil bag.

Outer package: fiber drum.

Packaging size: 25 kg/drum.

Our Advantage

We have branch offices in Dubai and India

we have own reliable & Long-term cooperative & experienced factory

Variety products for selection from China and India

We can customize according to your requirements

We can do OEM & ODM

We can offer N-1 to API

Upadacitinib CAS 1310726-60-3 API FAQ

Q: Is upadacitinib a JAK inhibitor?

A: Upadacitinib is FDA-approved for the treatment of moderate to severe rheumatoid arthritis (RA) that is unresponsive to first-line therapy. It is a second-generation selective Janus kinase (JAK) inhibitor targeting the JAK1 enzyme.

Q: What does upadacitinib block?

A: A protein called JAK, which increases inflammation in the body. Inflammation causes symptoms such as soreness, swelling and redness. Upadacitinib blocks JAK from working, which means there is less inflammation and a reduction in these symptoms.

Q: What is the CAS number of upadacitinib?

A: 1310726-60-3

Q: What is the therapeutic category of upadacitinib?

A: Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression.

Q: What is the medication upadacitinib used for?

A: Upadacitinib is used to treat ankylosing spondylitis (a condition in which the body attacks the joints of the spine and other areas, causing pain, swelling, and joint damage) in adults who are unable to take or who did not respond to one or more TNF inhibitor medication(s).

Q: How effective is upadacitinib?

A: More people had their Crohn's under control after taking upadacitinib for 12 weeks compared with people who had not been taking upadacitinib (placebo).

Hot Tags: upadacitinib cas 1310726-60-3, China upadacitinib cas 1310726-60-3 manufacturers, suppliers, factory, intermediate drying products, api for analyzing human data, laboratory intermediates, rubber intermediates, api for human characteristics, api for human data access